Congress Materials – 938th European College of Neuropsychopharmacology (ECNP 2025)
2025 938th European College of Neuropsychopharmacology | Oct 11-14 | Amsterdam, The Netherlands
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Adjunctive Lumateperone 42 mg Treatment in Major Depressive Disorder: Efficacy in Anhedonia and Across Broad Range of Depressive Symptoms
Michael E. Thase, Willie R. Earley, Susan G. Kozauer, Changzheng Chen, Hassan Lakkis, John B. Edwards
This document will be available on October 11th 2025
Efficacy of Adjunctive Lumateperone 42 mg Treatment Across Depression and Anhedonia Symptoms in Major Depressive Disorder
Willie R. Earley, Suresh Durgam, Susan G. Kozauer, Yifan Mo, Hassan Lakkis, William Rowe, Joseph F. Goldberg, Roger S. McIntyre
This document will be available on October 11th 2025
Evaluation of Sexual Function With Adjunctive Lumateperone in Patients With Major Depressive Disorder
Anita H. Clayton, Willie R. Earley, Susan G. Kozauer, Yifan Mo, John B. Edwards, Suresh Durgam
This document will be available on October 11th 2025
Long-Term Adjunctive Lumateperone Treatment in Major Depressive Disorder: Results From a Six-Month Open-Label Extension Study
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Changzheng Chen, Tobie Escher, Andrew J. Cutler
This document will be available on October 11th 2025
Lumateperone for the Prevention of Relapse in Patients with Schizophrenia: Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal, Phase 3 Trial
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Jennifer Lin, Hassan Lakkis, Tobie Escher, Giridhar Maddirevula, Christoph U. Correll
This document will be available on October 11th 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
